Form 4: Director Caley Castelein Receives Stock Option Grant

Whitehawk Therapeutics director Caley Castelein was granted 38,040 stock options with an exercise price of $4.16.

Summary

• Director Caley Castelein received a grant of 38,040 stock options on June 12, 2026.
• The options have an exercise price of $4.16 per share.
• The options are set to expire on June 12, 2036.
• Vesting occurs on the earlier of the one-year anniversary of the grant or the day before the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon the reporting person remaining a Service Provider under the 2021 Equity Incentive Plan.

Future Outlook

The options vest in full after one year or upon the next annual meeting, whichever comes first, incentivizing continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The grant structure follows standard industry practices for small-cap biotechnology firms using equity incentive plans to retain board talent.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on the earlier of June 12, 2027, or the day prior to the next annual meeting of stockholders.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Options, Director Compensation